These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34287610)

  • 21. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid plaques are still main target for Alzheimer's drugs.
    Hawkes N
    BMJ; 2016 Jan; 352():i214. PubMed ID: 26762356
    [No Abstract]   [Full Text] [Related]  

  • 23. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions.
    Sacks CA; Avorn J; Kesselheim AS
    N Engl J Med; 2017 May; 376(18):1706-1708. PubMed ID: 28467878
    [No Abstract]   [Full Text] [Related]  

  • 24. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.
    de la Torre JC; Gonzalez-Lima F
    J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943
    [No Abstract]   [Full Text] [Related]  

  • 25. The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point.
    Eiser AR
    Am J Med; 2021 Dec; 134(12):1442-1443. PubMed ID: 34256026
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA dependence on drug industry.
    Lawson GW
    J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
    [No Abstract]   [Full Text] [Related]  

  • 27. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 28. Aducanumab (Aduhelm) for Alzheimer's disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258
    [No Abstract]   [Full Text] [Related]  

  • 29. Aducanumab, amyloid, and culture wars.
    Iliffe S; Manthorpe J
    BMJ; 2021 Aug; 374():n2038. PubMed ID: 34413026
    [No Abstract]   [Full Text] [Related]  

  • 30. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 31. Dementia and antipsychotics: a prescription for problems.
    Berns A
    J Leg Med; 2012 Oct; 33(4):553-69. PubMed ID: 23216152
    [No Abstract]   [Full Text] [Related]  

  • 32. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 33. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 34. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
    Gleason A; Ayton S; Bush AI
    Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
    [No Abstract]   [Full Text] [Related]  

  • 35. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
    Alexander GC; Karlawish J
    Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
    [No Abstract]   [Full Text] [Related]  

  • 36. US FDA defends approval of Alzheimer's disease drug.
    Jaffe S
    Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 38. Questions EMERGE as Biogen claims aducanumab turnaround.
    Howard R; Liu KY
    Nat Rev Neurol; 2020 Feb; 16(2):63-64. PubMed ID: 31784690
    [No Abstract]   [Full Text] [Related]  

  • 39. Rapid drug access and scientific rigour: a delicate balance.
    The Lancet Neurology
    Lancet Neurol; 2021 Jan; 20(1):1. PubMed ID: 33340471
    [No Abstract]   [Full Text] [Related]  

  • 40. Aducanumab and the Business of Alzheimer Disease-Some Choice.
    Karlawish J
    JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.